Lineage Cell Therapeutics (LCTX) Osake Kurssi

Lineage Cell Therapeutics Inc is primarily active in the biotechnology and regenerative medicine industries.

The main competitors of Lineage Cell Therapeutics Inc in the market are reputable companies such as Fate Therapeutics Inc, bluebird bio Inc, and Celularity Inc.

Lineage Cell Therapeutics Inc, formerly known as BioTime Inc, is a clinical-stage biotechnology company focused on developing novel cell therapies for various diseases. With a rich history dating back to 1992, the company has been at the forefront of regenerative medicine research. Lineage Cell Therapeutics is dedicated to using its proprietary cell-based technologies to treat degenerative disorders and diseases. The company's extensive research expertise and collaborations have contributed to groundbreaking advancements in stem cell therapy. By leveraging its broad portfolio of cell lines, including pluripotent and progenitor cells, Lineage Cell Therapeutics aims to revolutionize the field of regenerative medicine and improve patient outcomes.

Lineage Cell Therapeutics Inc, a leading biotechnology company, has achieved significant milestones in its journey. The company has made breakthrough advancements in the field of cell therapy, focusing on regenerative medicine and developing innovative treatments for degenerative diseases. Lineage Cell Therapeutics has successfully completed multiple clinical trials, demonstrating the safety and efficacy of its promising cell-based therapies. Additionally, the company has gained regulatory approvals and collaborated with renowned medical institutions to further its research and development efforts. With a dedicated team of experts and a commitment to improving patients' lives, Lineage Cell Therapeutics continues to make strides in the field of regenerative medicine.

Lineage Cell Therapeutics Inc is primarily present in the United States.

Lineage Cell Therapeutics Inc represents values of innovation, dedication, and excellence in the field of cell therapy. The company's corporate philosophy revolves around utilizing the potential of stem cells to address unmet medical needs and improve patients' lives. With a focus on research and development, Lineage Cell Therapeutics Inc aims to deliver groundbreaking therapies that can revolutionize the treatment of age-related macular degeneration and other degenerative diseases. By harnessing the power of regenerative medicine, the company strives to offer hope and a better quality of life for patients worldwide.

13 analyytikkoa arvioi tällä hetkellä Lineage Cell Therapeutics-osaketta: 11 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Lineage Cell Therapeutics-yhtiöltä 15,16 M USD liikevaihtoa ja −0,06 USD osakekohtaista tulosta.

Lineage Cell Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Lineage Cell Therapeutics-osake noteerataan hintaan 0,89 EUR (1,00 USD).

Lineage Cell Therapeutics-osake (LCTX) on listattuna 3 pörssissä, muun muassa: Frankfurt (BT3.F).

Lineage Cell Therapeutics Inc is a US-based company specializing in the development of cell therapies for the treatment of various diseases. The company's business model is based on the production and marketing of cell therapies derived from human embryonic stem cells. The company has various divisions, including neurology, ophthalmology, immunology, and oncology. In neuroscience, the company focuses on the therapy of spinal cord injuries, strokes, Alzheimer's disease, and other neurodegenerative diseases. In ophthalmology, the company focuses on the treatment of retinal diseases such as age-related macular degeneration and diabetic retinopathy. In immunology, Lineage Cell Therapeutics focuses on the treatment of autoimmune diseases such as type 1 diabetes and multiple sclerosis. In oncology, the company focuses on the development of cancer immunotherapies. The flagship product of Lineage Cell Therapeutics is OpRegen, a cell therapy for the treatment of retinal diseases. OpRegen is a product derived from pluripotent stem cells. It is currently in clinical trials, and the company hopes to bring it to market in the near future. Another product of Lineage Cell Therapeutics is OPC1, a cell therapy for the treatment of spinal cord injuries. OPC1 utilizes human embryonic stem cells differentiated into oligodendrocytes to repair damaged nerve fibers in the spinal cord. The product is currently in phase 1/2 studies. Lineage Cell Therapeutics is also working on the development of cancer immunotherapies based on the use of genetically modified T cells that can recognize and attack cancer cells. These therapies aim to provide more effective and targeted treatment for cancer. The company's business model involves the development and marketing of cell therapies derived from human embryonic stem cells. Lineage Cell Therapeutics works closely with academic institutions and research partners to develop new treatments and expand therapy options for patients. To further expand its business model, the company has undertaken various strategic partnerships and acquisitions. In 2018, Lineage Cell Therapeutics acquired Asterias Biotherapeutics to strengthen its position in the treatment of spinal cord injuries. In the same year, the company also entered into a partnership with Cancer Research UK to develop new cancer immunotherapies. In summary, Lineage Cell Therapeutics Inc is a company specializing in the development and marketing of cell therapies for the treatment of various diseases. The company's business model is based on the use of human embryonic stem cells and a diverse product portfolio encompassing various divisions, including neuroscience, ophthalmology, immunology, and oncology. Through strategic partnerships and acquisitions, the company aims to strengthen its position in the industry and continue its mission to develop innovative treatment options for patients in need.

odotettu liikevaihto Lineage Cell Therapeutics on 15,16 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Lineage Cell Therapeutics on −13,48 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Lineage Cell Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −17,07. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Lineage Cell Therapeutics-osakkeen arvostusta.

Lineage Cell Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 15,17. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Lineage Cell Therapeutics-osakkeen arvostuskennuslukuna.

Lineage Cell Therapeutics:n Eulpool-laatuscore on 3/10.

Lineage Cell Therapeutics:n ISIN on US53566P1093. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Lineage Cell Therapeutics:n WKN on A2PP89. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Lineage Cell Therapeutics:n ticker on LCTX. Tämä pörssinoteeraus käytetään Lineage Cell Therapeutics-osakkeiden kauppaan pörssissä.